- Topic
5k Popularity
9k Popularity
8k Popularity
5k Popularity
658 Popularity
- Pin
- 📢 Gate Square Exclusive: #PUBLIC Creative Contest# Is Now Live!
Join Gate Launchpool Round 297 — PublicAI (PUBLIC) and share your post on Gate Square for a chance to win from a 4,000 $PUBLIC prize pool
🎨 Event Period
Aug 18, 2025, 10:00 – Aug 22, 2025, 16:00 (UTC)
📌 How to Participate
Post original content on Gate Square related to PublicAI (PUBLIC) or the ongoing Launchpool event
Content must be at least 100 words (analysis, tutorials, creative graphics, reviews, etc.)
Add hashtag: #PUBLIC Creative Contest#
Include screenshots of your Launchpool participation (e.g., staking record, reward - 🎉 Hey Gate Square friends! Non-stop perks and endless excitement—our hottest posting reward events are ongoing now! The more you post, the more you win. Don’t miss your exclusive goodies! 🚀
🆘 #Gate 2025 Semi-Year Community Gala# | Square Content Creator TOP 10
Only 1 day left! Your favorite creator is one vote away from TOP 10. Interact on Square to earn Votes—boost them and enter the prize draw. Prizes: iPhone 16 Pro Max, Golden Bull sculpture, Futures Vouchers!
Details 👉 https://www.gate.com/activities/community-vote
1️⃣ #Show My Alpha Points# | Share your Alpha points & gains
Post your - 💙 Gate Square #Gate Blue Challenge# 💙
Show your limitless creativity with Gate Blue!
📅 Event Period
August 11 – 20, 2025
🎯 How to Participate
1. Post your original creation (image / video / hand-drawn art / digital work, etc.) on Gate Square, incorporating Gate’s brand blue or the Gate logo.
2. Include the hashtag #Gate Blue Challenge# in your post title or content.
3. Add a short blessing or message for Gate in your content (e.g., “Wishing Gate Exchange continued success — may the blue shine forever!”).
4. Submissions must be original and comply with community guidelines. Plagiarism or re
Anglikan: The only innovative drug project currently under research is ALK-N001.
Golden Ten Data on June 9, Anglikang issued a change announcement, the company's shares for 2 consecutive trading days closing price deviation of more than 20%, belongs to the abnormal fluctuation of stock trading. The company's current innovative drug project under development is only ALK-N001, which obtained the drug clinical trial approval notice in April 2025 and is still in the phase I clinical trial stage as of the disclosure date of this announcement. The R&D of innovative drugs has the characteristics of long cycle, large investment and high uncertainty, so investors should pay attention to investment risks.